| Nov 2026 | ||||||
|---|---|---|---|---|---|---|
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
| 01 | ||||||
| 02 | 03 | 04 | 05 Risk Management of Raw Materials in a GMP Environment | 06 | 07 | 08 |
| 09 | 10 | 11 Biofilms: A Guide for QA, Compliance, and Bioprocessing Teams | 12 Responding to FDA Form 483 Observations at the Conclusion of a Drug cGMP Inspection | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 Disinfectant Validation and Efficacy Testing | 26 | 27 | 28 | 29 |
| 30 | ||||||
| Prev Next | ||||||